


FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

U.S. PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Name	Class	Subclass	Filing Date
AH ↓	1	4,968,603	06.11.90	Slamon et al.			
	2	5,183,884	02.02.93	Kraus et al.			
	3	5,480,968	02.01.96	Kraus et al.			
	4	5,641,869	24.06.97	Vandlen et al.			
	5	5,677,171	14.10.97	Hudziak et al.			
	6	5,783,186	21.07.98	Arakawa et al.			
	7	5,821,337	13.10.98	Carter et al.			
	8	5,824,311	20.10.98	Greene et al.			

RECEIVED

DEC 06 2000

TECH CENTER 1600/2500

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation Yes	No
AH ↓	9	599,274	01.06.94	EPO				
	10	WO 90/14357	29.11.90	PCT				
	11	WO 92/20798	26.11.92	PCT				
	12	WO 94/00136	06.01.94	PCT				
	13	WO 94/22478	13.10.94	PCT				
	14	WO 97/35885	02.10.97	PCT				
	15	WO 98/02540	22.01.98	PCT				
	16	WO 98/02541	22.01.98	PCT				
	17	WO 98/17797	30.04.98	PCT				
	18	WO 99/39729	12.08.99	PCT				

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

AH ↓	19	Aasland et al., "Expression of oncogenes in thyroid tumours: Coexpression of c-erbB2/neu and c-erbB" <u>British Journal of Cancer</u> 57(4):358-363 (Apr 1988)
	20	Akiyama et al., "Tumor Promoter and Epidermal Growth Factor Stimulate Phosphorylation of the c-erbB-2 Gene Product in MKN-7 Human Adenocarcinoma Cells" <u>Molecular & Cellular Biology</u> 8(3):1019-1026 (Mar 1988)
	21	Arteaga et al., "p185 ^{c-erbB-2} Signaling Enhances Cisplatin-induced Cytotoxicity in Human Breast Carcinoma Cells: Association Between an Oncogenic Receptor Tyrosine Kinase and Drug-induced DNA Repair" <u>Cancer Research</u> 54(14):3758-3765 (Jul 15, 1994)
	22	Bacus et al., "Differentiation of Cultured Human Breast Cancer Cells (AU-565 and MCF-7) Associated With Loss of Cell Surface HER-2/neu Antigen" <u>Molecular Carcinogenesis</u> 3(6):350-362 (1990)
	23	Bacus et al., "Tumor-inhibitory Monoclonal Antibodies to the HER-2/Neu Receptor Induce Differentiation of Human Breast Cancer Cells" <u>Cancer Research</u> 52(9):2580-2589 (May 1, 1992)
	24	Baselga et al., "Phase II Study of Weekly Intravenous Recombinant Humanized Anti-p185 ^{HER2} Monoclonal Antibody in Patients With HER2/neu-Overexpressing Metastatic Breast Cancer" <u>J. Clin. Oncol.</u> 14(3):737-744 (Mar 1996)
↓	25	Baselga et al., "Receptor Blockade With Monoclonal Antibodies As Anti-Cancer Therapy" <u>Pharmac. Ther.</u> 64:127-154 (1994)
	26	Borst et al., "Oncogene Alterations in Endometrial Carcinoma" <u>Gynecologic Oncology</u> 38(3):364-366 (Sep 1990)


Examiner

Date Considered

12/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ALH	27	Burden et al., "Neuregulins and their receptors: a versatile signaling module in organogenesis and oncogenesis" <u>Neuron</u> 18(6):847-855 (Jun 1997)
	28	Carraway et al., "A Neu Acquaintance for ErbB3 and ErbB4: A Role for Receptor Heterodimerization in Growth Signaling" <u>Cell</u> 78:5-8 (Jul 15, 1994)
	29	Carraway et al., "Neuregulin-2, a new ligand of ErbB3/ErbB4-receptor tyrosine kinases" <u>Nature</u> 387:512-516 (May 1997)
	30	Carter et al., "Humanization of an anti-p185HER2 antibody for human cancer therapy" <u>Proc. Natl. Acad. Sci.</u> 89:4285-4289 (May 1992)
	31	Chang et al., "Ligands for ErbB-family receptors encoded by a neuregulin-like gene" <u>Nature</u> 387:509-512 (May 29, 1997)
	32	Cohen et al., "Expression pattern of the neu (NGL) gene-encoded growth factor receptor protein (p185neu) in normal and transformed epithelial tissues of the digestive tract" <u>Oncogene</u> 4(1):81-88 (Jan 1989)
	33	Connelly et al., "The epidermal growth factor receptor and the product of the neu protooncogene are members of a receptor tyrosine phosphorylation cascade" <u>Proc. Natl. Acad. Sci. USA</u> 87:6054-6057 (Aug 1990)
	34	Craft et al., "A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase" <u>Nature Medicine</u> 5(3):280-285 (Mar 1999)
	35	D'souza et al., "Overexpression of ERBB2 in human mammary epithelial cells signals inhibition of transcription of the E-cadherin gene" <u>Proc. Natl. Acad. Sci. USA</u> 91(15):7202-7206 (Jul 19, 1994)
	36	Drebin et al., "Down-Modulation of an Oncogene Protein Product and Reversion of the Transformed Phenotype by Monoclonal Antibodies" <u>Cell</u> 41(3):695-706 (Jul 1985)
	37	Drebin et al., "Monoclonal antibodies reactive with distinct domains of the neu oncogene-encoded p185 molecule exert synergistic anti-tumor effects in vivo" <u>Oncogene</u> 2:273-277 (1988)
	38	Earp et al., "Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research" <u>Breast Cancer Res and Treatment</u> 35:115-132 (1995)
	39	Fendly et al., "Characterization of Murine Monoclonal Antibodies Reactive to Either the Human Epidermal Growth Factor Receptor or HER2/neu Gene Product" <u>Cancer Research</u> 50:1550-1558 (Mar 1, 1990)
	40	Fukushige et al., "Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line" <u>Molecular & Cellular Biology</u> 6(3):955-958 (Mar 1986)
	41	Goldman et al., "Heterodimerization of the erbB-1 and erbB-2 Receptors in Human Breast Carcinoma Cells: A Mechanism for Receptor Transregulation" <u>Biochemistry</u> 29(50):11024-11028 (1990)
	42	Graus-Porta et al., "ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling" <u>EMBO Journal</u> 16(7):1647-1655 (1997)
	43	Groenen et al., "Structure-Function Relationships for the EGF/TGF- α Family of Mitogens" <u>Growth Factors</u> 11:235-257 (1994)
	44	Gu et al., "Overexpression of her-2/neu in human prostate cancer and benign hyperplasia" <u>Cancer Lett.</u> 99:185-189 (1996)
	45	Guerin et al., "Overexpression of Either c-myc or c-erbB-2/neu Proto-Oncogenes in Human Breast Carcinomas: Correlation with Poor Prognosis" <u>Oncogene Res</u> 3:21-31 (1988)
V	46	Hancock et al., "A Monoclonal Antibody against the c-erbB-2 Protein Enhances the Cytotoxicity of cis-Diamminedichloroplatinum against Human Breast and Ovarian Tumor Cell Lines" <u>Cancer Research</u> 51:4575-4580 (Sep 1, 1991)

Examiner

Date Considered

12/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

47	Harari et al., "Neuregulin-4: a novel growth factor that acts through the ErbB-4 receptor tyrosine kinase" <u>Oncogene</u> 18:2681-2689 (1999)
48	Harwerth et al., "Monoclonal Antibodies against the Extracellular Domain of the erbB-2 Receptor Function as Partial Ligand Agonists" <u>Journal of Biological Chemistry</u> 267(21):15160-15167 (Jul 25, 1992)
49	Holmes et al., "Identification of Heregulin, a Specific Activator of p185 ^{erbB2} " <u>Science</u> 256:1205-1210 (May 22, 1992)
50	Hudziak et al., "Increased expression of the putative growth factor receptor p185 ^{HER2} causes transformation and tumorigenesis of NIH 3T3 cells" <u>Proc. Natl. Acad. Sci.</u> 84(20):7159-7163 (Oct 1987)
51	Hudziak et al., "p185 ^{HER2} Monoclonal Antibody Has Antiproliferative Effects In Vitro and Sensitizes Human Breast Tumor Cells to Tumor Necrosis Factor" <u>Molecular & Cellular Biology</u> 9(3):1165-1172 (Mar 1989)
52	Jones et al., "Binding Interaction of the Heregulin β egf Domain with ErbB3 and ErbB4 Receptors Assessed by Alanine Scanning Mutagenesis" <u>Journal of Biological Chemistry</u> 273(19):11667-11674 (May 8, 1998)
53	Kannan et al., "Cripto Enhances the Tyrosine Phosphorylation of Shc and Activates Mitogen-activated Protein Kinase (MAPK) in Mammary Epithelial Cells" <u>Journal of Biological Chemistry</u> 272(6):3330-3335 (Feb 7, 1997)
54	Karunagaran et al., "ErbB-2 is a Common Auxiliary Subunit of NDF and EGF Receptors: Implications for Breast Cancer" <u>EMBO Journal</u> 15(2):254-264 (1996)
55	Kasprzyk et al., "Therapy of an Animal Model of Human Gastric Cancer Using a Combination of Anti-erbB-2 Monoclonal Antibodies" <u>Cancer Research</u> 52(10):2771-2776 (May 15, 1992)
56	Kern et al., "p185 ^{neu} Expression in Human Lung Adenocarcinomas Predicts Shortened Survival" <u>Cancer Research</u> 50(16):5184-5191 (Aug 15, 1990)
57	King et al., "Amplification of a Novel v-erbB-Related Gene in a Human Mammary Carcinoma" <u>Science</u> 229:974-976 (Sept 1985)
58	King et al., "EGF binding to its receptor triggers a rapid tyrosine phosphorylation of the erbB-2 protein in the mammary tumor cell line SK-BR-3" <u>EMBO Journal</u> 7(6):1647-1651 (1988)
59	Klapper et al., "A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors" <u>Oncogene</u> 14:2099-2109 (1997)
60	Kokai et al., "Synergistic Interaction of p185 ^{c-neu} and the EGF Receptor Leads to Transformation of Rodent Fibroblasts" <u>Cell</u> 58:287-292 (Jul 28, 1989)
61	Kotts et al., "Differential Growth Inhibition of Human Carcinoma Cells Exposed to Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" <u>In Vitro</u> (Abstract #176) 26(3):59A (1990)
62	Kotts et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-Gamma and Monoclonal Antibodies Directed Against the Extracellular Domain of the Her2/erbB2 Oncogene Protein" <u>FASEB Journal</u> (abstract #1470) 4(7):A1946 (1990)
63	Kotts et al., "Growth Inhibition of Human Breast Carcinoma Cells Exposed to Combinations of Interferon-gamma and Monoclonal Antibodies Directed against the Extracellular Domain of the HER2/ERBB2 Protooncogene" (Program 1470, Joint Mtg of ASBMB & AAI in New Orleans, LA on June 4-7, 1990 poster)
64	Kraus et al., "Isolation and characterization of ERBB3, a third member of the ERBB/epidermal growth factor receptor family: Evidence for overexpression in a subset of human mammary tumors" <u>Proc. Natl. Acad. Sci. USA</u> 86:9193-9197 (Dec 1989)
65	Kumar et al., "Regulation of Phosphorylation of the c-erbB-2/HER2 Gene Product by a Monoclonal Antibody and Serum Growth Factor(s) in Human Mammary Carcinoma Cells" <u>Molecular & Cellular Biology</u> 11(2):979-986 (Feb 1991)
66	Lee et al., "Transforming Growth Factor α : Expression, Regulation, and Biological Activities" <u>Pharmacological Reviews</u> 47(1):51-85 (Mar 1995)


Examiner

Date Considered

12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)


Alt	67	Lemke, G., "Neuregulins in Development" <u>Molecular and Cellular Neuroscience</u> 7:247-262 (1996)
	68	Levi et al., "The Influence of Heregulins on Human Schwann Cell Proliferation" <u>J. Neuroscience</u> 15(2):1329-1340 (Feb 1995)
	69	Lewis et al., "Differential responses of human tumor cell lines to anti-p185 ^{HER2} monoclonal antibodies" <u>Cancer Immunol. Immunother.</u> 37:255-263 (1993)
	70	Lewis et al., "Growth Regulation of Human Breast and Ovarian Tumor Cells by Heregulin: Evidence for the Requirement of ErbB2 as a Critical Component in Mediating Heregulin Responsiveness" <u>Cancer Research</u> 56:1457-1465 (Mar 15, 1996)
	71	Maler et al., "Requirements for the Internalization of a Murine Monoclonal Antibody Directed against the HER-2/neu Gene Product c-erbB-2" <u>Cancer Research</u> 51(19):5361-5369 (Oct 1, 1991)
	72	Masui et al., "Growth Inhibition of Human Tumor Cells in Athymic Mice by Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies" <u>Cancer Research</u> 44(3):1002-1007 (Mar 1984)
	73	McCann et al., "c-erbB-2 Oncoprotein Expression in Primary Human Tumors" <u>Cancer</u> 65(1):88-92 (Jan 1, 1990)
	74	McKenzie et al., "Generation and characterization of monoclonal antibodies specific for the human neu oncogene product, p185" <u>Oncogene</u> 4:543-548 (1989)
	75	"Could Medarex's MAb be prostate cancer's Herceptin?" <u>Scrip</u> 2442:25 (Jun 2, 1999)
	76	Morrissey et al., "Axon-induced mitogenesis of human Schwann cells involves heregulin and p185 ^{erbB2} " <u>Proc. Natl. Acad. Sci. USA</u> 92:1431-1435 (Feb 1995)
	77	Myers et al., "Biological Effects of Monoclonal Antireceptor Antibodies Reactive with neu Oncogene Product, p185 ^{neu} " <u>Methods in Enzymology</u> 198:277-290 (1991)
	78	Park et al., "Amplification, Overexpression, and Rearrangement of the erbB-2 Protooncogene in Primary Human Stomach Carcinomas" <u>Cancer Research</u> 49(23):6605-6609 (Dec 1, 1989)
	79	Pietras et al., "Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells" <u>Oncogene</u> 9:1829-1838 (1994)
	80	Plowman et al., "Heregulin induces tyrosine phosphorylation of HER4/p180 ^{erbB4} " <u>Nature</u> (Letters to Nature) 366:473-475 (Dec 2, 1993)
	81	Plowman et al., "Ligand-specific activation of HER4/p180 ^{erbB4} , a fourth member of the epidermal growth factor receptor family" <u>Proc. Natl. Acad. Sci. USA</u> 90:1746-1750 (Mar 1993)
	82	Presta et al., "Humanization of an Anti-Vascular Endothelial Growth Factor Monoclonal Antibody for the Therapy of Solid Tumors and Other Disorders" <u>Cancer Research</u> 57(20):4593-4599 (Oct 15, 1997)
	83	Ross et al., "HER-2/neu Gene Amplification Status in Prostate Cancer by Fluorescence in Situ Hybridization" <u>Hum. Pathol.</u> 28(7):827-833 (July 1997)
	84	Ross et al., "Prognostic Significance of HER-2/neu Gene Amplification Status by Fluorescence In Situ Hybridization of Prostate Carcinoma" <u>Cancer</u> 79(11):2162-2170 (June 1, 1997)
	85	Sadasivan et al., "Overexpression of Her-2/Neu May Be An Indicator of Poor Prognosis in Prostate Cancer" <u>J. Urol.</u> 150:126-131 (Jul 1993)
	86	Sarup et al., "Characterization of an Anti-P185 ^{HER2} Monoclonal Antibody that Stimulates Receptor Function and Inhibits Tumor Cell Growth" <u>Growth Regulation</u> 1:72-82 (1991)

Examiner

Date Considered

12/21/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

ALH	87	Schaefer et al., "A Discrete Three-amino Acid Segment (LVI) at the C-terminal End of Kinase-impaired ErbB3 is required for Transactivation of ErbB2" <u>Journal of Biological Chemistry</u> 274(2):859-866 (Jan 8, 1999)
	88	Schaefer et al., "γ-Heregulin: a novel heregulin isoform that is an autocrine growth factor for the human breast cancer cell line, MDA-MB-175" <u>Oncogene</u> 15:1385-1394 (1997)
	89	Scher et al., "Changing Pattern of Expression of the Epidermal Growth Factor Receptor and Transforming Growth Factor α in the Progression of Prostatic Neoplasms" <u>Clinical Cancer Research</u> 1:545-550 (May 1995)
	90	Scott et al., "p185 ^{HER2} Signal Transduction in Breast Cancer Cells" <u>Journal of Biological Chemistry</u> 266(22):14300-14305 (Aug 5, 1991)
	91	Shawver et al., "Ligand-like Effects Induced by Anti-c-erbB-2 Antibodies Do Not Correlate with and Are Not Required for Growth Inhibition of Human Carcinoma Cells" <u>Cancer Research</u> 54(5):1367-1373 (Mar 1, 1994)
	92	Sheng et al., "Inhibition of Human Colon Cancer Cell Growth by Selective Inhibition of Cyclooxygenase-2" <u>J. Clin. Invest.</u> 99(9):2254-2259 (May 1997)
	93	Shepard et al., "Monoclonal Antibody Therapy of Human Cancer: Taking the HER2 Protooncogene to the Clinic" <u>J. Clin. Immunol.</u> 11(3):117-127 (1991)
	94	Slamon et al., "Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/neu Oncogene" <u>Science</u> 235:177-182 (Jan 9, 1987)
	95	Slamon et al., "Studies of the HER-2/neu Proto-oncogene in Human Breast and Ovarian Cancer" <u>Science</u> 244:707-712 (May 12, 1989)
	96	Sliwkowski et al., "Coexpression of erbB2 and erbB3 Proteins Reconstitutes a High Affinity Receptor for Heregulin" <u>Journal of Biological Chemistry</u> 269(20):14661-14665 (May 20, 1994)
	97	Stancovski et al., "Mechanistic aspects of the opposing effects of monoclonal antibodies to the ERBB2 receptor on tumor growth" <u>Proc. Natl. Acad. Sci. USA</u> 88(19):8691-8695 (Oct 1, 1991)
	98	Stern et al., "EGF-stimulated Tyrosine Phosphorylation of p185 ^{neu} : a potential model for receptor interactions" <u>EMBO Journal</u> 7(4):995-1001 (1988)
	99	Tagliabue et al., "Selection of monoclonal antibodies which induce internalization and phosphorylation of p185 ^{HER2} and growth inhibition of cells with HER2/NEU gene amplification" <u>International Journal of Cancer</u> 47(6):933-937 (Apr 1, 1991)
	100	Vadlamudi et al., "Regulation of Cyclooxygenase-2 pathway by HER2 receptor" <u>Oncogene</u> 18:305-314 (1999)
	101	Vitetta et al., "Monoclonal Antibodies as Agonists: An Expanded Role for Their Use in Cancer Therapy" <u>Cancer Research</u> 54(20):5301-5309 (Oct 15, 1994)
	102	Wada et al., "Intermolecular Association of the p185 ^{neu} Protein and EGF Receptor Modulates EGF Receptor Function" <u>Cell</u> 61:1339-1347 (Jun 29, 1990)
	103	Weiner et al., "Expression of the neu Gene-encoded Protein (P185 ^{neu}) in Human Non-Small Cell Carcinomas of the Lung" <u>Cancer Research</u> 50(2):421-425 (Jan 15, 1990)
	104	Werther et al., "Humanization of an Anti-Lymphocyte Function-Associated Antigen (LFA)-1 Monoclonal Antibody and Reengineering of the Humanized Antibody for Binding to Rhesus LFA-1" <u>J. of Immunology</u> 157:4986-4995 (1996)
	105	Williams et al., "Expression of c-erbB-2 in Human Pancreatic Adenocarcinomas" <u>Pathobiology</u> 59(1):46-52 (1991)
	106	Wofsy et al., "Modification and Use of Antibodies to Label Cell Surface Antigens" <u>Selected Methods in Cellular Immunology</u> , Mishel and Schiigi, eds., San Francisco:WJ Freeman Co., Chapter 13, pps. 287-304 (1980)

Examiner

Date Considered

12/29/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

U.S. Dept. of Commerce
Patent and Trademark Office

P1467R2

09/602.812

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

To Be Assigned

(Use several sheets if necessary)

[illegible]

Examiner

Date Considered

12/24/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

APR 14 2001

APR 12 2001

U.S. Dept. of Commerce
Patent and Trademark Office

Atty Docket No.

P1467R2

Serial No.

09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT

(Use several sheets if necessary)

Applicant

Adams et al.

Filing Date

23 Jun 2000

Group

1644

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
Alt	219	WO 00/69460	23.11.00	PCT				
Alt	220	WO 01/00238 A1	04.01.01	PCT				
Alt	221	WO 01/00244 A2	04.01.01	PCT				
Alt	222	WO 01/15730 A1	08.03.01	PCT				

RECEIVED

APR 16 2001

TECH CENTER 1600/2900

Examiner

Anne L. Sullivan

Date Considered

Oct 21, 2002

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449

U.S. Dept. of Commerce
Patent and Trademark OfficeAtty Docket No.
P1467R2Serial No.
09/602,812

LIST OF DISCLOSURES CITED BY APPLICANT


(Use several sheets if necessary)

Applicant
Adams et al.Filing Date
23 Jun 2000Group
1642

FOREIGN PATENT DOCUMENTS

Examiner Initials		Document Number	Date	Country	Class	Subclass	Translation	
							Yes	No
RLH	223	WO 00/61145	19.10.00	PCT				


Examiner



Date Considered

12/22/03

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449		U.S. Dept. of Commerce Patent and Trademark Office		Atty Docket No. P1467R2	Serial No. 09/602,812	
LIST OF DISCLOSURES CITED BY APPLICANT (Use several sheets if necessary)				Applicant Adams et al.		
				Filing Date 23 Jun 2000	Group 1642	
FOREIGN PATENT DOCUMENTS						
Examiner Initials	Document Number	Date	Country	Class	Subclass	Translation Yes No
	226 WO 00/78347	28.12.00	PCT			<p>RECEIVED</p> <p>JUL 31 2002</p> <p>TECH CENTER 1600/2900</p>
Examiner <i>Anne L. Hollensen</i>				Date Considered <i>Oct 21, 2002</i>		
*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.						

U.S. Dept. of Commerce
Patent and Trademark Office

P1467R2

09/602,812

Applicant

Adams et al.

(Use several sheets if necessary)

Filing Date

23 Jun 2000

Group

1642

OTHER DISCLOSURES (Including Author, Title, Date, Pertinent Pages, etc.)

[illegible]

Examiner

Anne C Hallman

Date Considered

11/17/2003

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.